-
1
-
-
84867253160
-
The application and mechanism of action of ribavirin in therapy of hepatitis C
-
Thomas E, Ghany MG, Liang TJ. The application and mechanism of action of ribavirin in therapy of hepatitis C. Antivir Chem Chemother 2013;23:1-12.
-
(2013)
Antivir Chem Chemother
, vol.23
, pp. 1-12
-
-
Thomas, E.1
Ghany, M.G.2
Liang, T.J.3
-
2
-
-
82955163230
-
Ribavirin for the treatment of chronic hepatitis C virus infection: A review of the proposed mechanisms of action
-
Paeshuyse J, Dallmeier K, Neyts J. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Curr Opin Virol 2011;1:590-8.
-
(2011)
Curr Opin Virol
, vol.1
, pp. 590-598
-
-
Paeshuyse, J.1
Dallmeier, K.2
Neyts, J.3
-
4
-
-
0038820380
-
Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin
-
Layden-Almer JE, Ribeiro RM, Wiley T, et al. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatol Baltim Md 2003;37:1343-50.
-
(2003)
Hepatol Baltim Md
, vol.37
, pp. 1343-1350
-
-
Layden-Almer, J.E.1
Ribeiro, R.M.2
Wiley, T.3
-
5
-
-
84878169408
-
Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients
-
Dietz J, Schelhorn S-E, Fitting D, et al. Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients. J Virol 2013;87:6172-81.
-
(2013)
J Virol
, vol.87
, pp. 6172-6181
-
-
Dietz, J.1
Schelhorn, S.-E.2
Fitting, D.3
-
6
-
-
0035076685
-
Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy
-
Querenghi F, Yu Q, Billaud G, et al. Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy. J Viral Hepat 2001;8:120-31.
-
(2001)
J Viral Hepat
, vol.8
, pp. 120-131
-
-
Querenghi, F.1
Yu, Q.2
Billaud, G.3
-
7
-
-
34247552260
-
Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy
-
Lutchman G, Danehower S, Song B-C, et al. Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology 2007;132:1757-66.
-
(2007)
Gastroenterology
, vol.132
, pp. 1757-1766
-
-
Lutchman, G.1
Danehower, S.2
Song, B.-C.3
-
8
-
-
84908174040
-
Effects of ribavirin monotherapy on the viral population in patients with chronic hepatitis C genotype 1: Direct sequencing and pyrosequencing of the HCV regions
-
Quiles-Pérez R, Muñoz-de-Rueda P, Maldonado AM-L, et al. Effects of ribavirin monotherapy on the viral population in patients with chronic hepatitis C genotype 1: direct sequencing and pyrosequencing of the HCV regions. J Med Virol 2014;86:1886-97.
-
(2014)
J Med Virol
, vol.86
, pp. 1886-1897
-
-
Quiles-Pérez, R.1
Muñoz-De-Rueda, P.2
Maldonado, A.M.-L.3
-
9
-
-
34447248532
-
Analysis of ribavirin mutagenicity in human hepatitis C virus infection
-
Chevaliez S, Brillet R, Lázaro E, et al. Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J Virol 2007;81:7732-41.
-
(2007)
J Virol
, vol.81
, pp. 7732-7741
-
-
Chevaliez, S.1
Brillet, R.2
Lázaro, E.3
-
10
-
-
0028825313
-
Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial
-
Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:897-903.
-
(1995)
Ann Intern Med
, vol.123
, pp. 897-903
-
-
Di Bisceglie, A.M.1
Conjeevaram, H.S.2
Fried, M.W.3
-
11
-
-
10344259671
-
Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study
-
Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996;25:591-8.
-
(1996)
J Hepatol
, vol.25
, pp. 591-598
-
-
Dusheiko, G.1
Main, J.2
Thomas, H.3
-
12
-
-
0030227143
-
Prolonged therapy of chronic hepatitis C with ribavirin
-
Hoofnagle JH, Lau D, Conjeevaram H, et al. Prolonged therapy of chronic hepatitis C with ribavirin. J Viral Hepat 1996;3:247-52.
-
(1996)
J Viral Hepat
, vol.3
, pp. 247-252
-
-
Hoofnagle, J.H.1
Lau, D.2
Conjeevaram, H.3
-
13
-
-
0031831349
-
Ribavirin monotherapy in patients with chronic hepatitis C: A retrospective study of 95 patients
-
Zoulim F, Haem J, Ahmed SS, et al. Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. J Viral Hepat 1998;5:193-8.
-
(1998)
J Viral Hepat
, vol.5
, pp. 193-198
-
-
Zoulim, F.1
Haem, J.2
Ahmed, S.S.3
-
14
-
-
84860322902
-
New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives
-
Welsch C, Jesudian A, Zeuzem S, et al. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 2012;61(Suppl 1): i36-46.
-
(2012)
Gut
, vol.61
, pp. i36-46
-
-
Welsch, C.1
Jesudian, A.2
Zeuzem, S.3
-
15
-
-
84871814966
-
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C
-
Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368:34-44.
-
(2013)
N Engl J Med
, vol.368
, pp. 34-44
-
-
Gane, E.J.1
Stedman, C.A.2
Hyland, R.H.3
-
16
-
-
84899068302
-
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin
-
Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1594-603.
-
(2014)
N Engl J Med
, vol.370
, pp. 1594-1603
-
-
Feld, J.J.1
Kowdley, K.V.2
Coakley, E.3
-
17
-
-
84901036125
-
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis
-
Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973-82.
-
(2014)
N Engl J Med
, vol.370
, pp. 1973-1982
-
-
Poordad, F.1
Hezode, C.2
Trinh, R.3
-
18
-
-
84925351743
-
High efficacy of treatment with Sofosbuvir+ GS-5816+/-Ribavirin for 12 weeks in treatment experienced patients with genotype 1 or 3 HCV Infection
-
Pianko S, Flamm S, Shiffman M, et al. High efficacy of treatment with Sofosbuvir+ GS-5816+/-Ribavirin for 12 weeks in treatment experienced patients with genotype 1 or 3 HCV Infection. Hepatology 2014;60:297A-8A.
-
(2014)
Hepatology
, vol.60
, pp. 297A-298A
-
-
Pianko, S.1
Flamm, S.2
Shiffman, M.3
-
19
-
-
84920990853
-
Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: Preliminary results of a prospective, multicenter study
-
Flamm S, Everson G, Charlton M, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. Hepatology 2014;60:320A-1A.
-
(2014)
Hepatology
, vol.60
, pp. 320A-3201A
-
-
Flamm, S.1
Everson, G.2
Charlton, M.3
-
20
-
-
36348960622
-
Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response
-
Feld JJ, Nanda S, Huang Y, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatol Baltim Md 2007;46:1548-63.
-
(2007)
Hepatol Baltim Md
, vol.46
, pp. 1548-1563
-
-
Feld, J.J.1
Nanda, S.2
Huang, Y.3
-
21
-
-
81155131454
-
Ribavirin enhances IFN-α signalling and MxA expression: A novel immune modulation mechanism during treatment of HCV
-
Stevenson NJ, Murphy AG, Bourke NM, et al. Ribavirin enhances IFN-α signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV. PloS ONE 2011;6:e27866.
-
(2011)
PloS ONE
, vol.6
-
-
Stevenson, N.J.1
Murphy, A.G.2
Bourke, N.M.3
-
22
-
-
78751545582
-
Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models
-
Thomas E, Feld JJ, Li Q, et al. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatol Baltim Md 2011;53:32-41.
-
(2011)
Hepatol Baltim Md
, vol.53
, pp. 32-41
-
-
Thomas, E.1
Feld, J.J.2
Li, Q.3
-
23
-
-
84863251369
-
Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8
-
Tokumoto Y, Hiasa Y, Uesugi K, et al. Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8. J Infect Dis 2012;205:1121-30.
-
(2012)
J Infect Dis
, vol.205
, pp. 1121-1130
-
-
Tokumoto, Y.1
Hiasa, Y.2
Uesugi, K.3
-
24
-
-
84889635179
-
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C
-
Rotman Y, Noureddin M, Feld JJ, et al. Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut 2014;63:161-9.
-
(2014)
Gut
, vol.63
, pp. 161-169
-
-
Rotman, Y.1
Noureddin, M.2
Feld, J.J.3
-
25
-
-
41149156316
-
Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C
-
Asselah T, Bieche I, Narguet S, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008;57:516-24.
-
(2008)
Gut
, vol.57
, pp. 516-524
-
-
Asselah, T.1
Bieche, I.2
Narguet, S.3
-
26
-
-
19044361835
-
Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection
-
Chen L, Borozan I, Feld J, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005;128:1437-44.
-
(2005)
Gastroenterology
, vol.128
, pp. 1437-1444
-
-
Chen, L.1
Borozan, I.2
Feld, J.3
-
28
-
-
50249171227
-
Neutral red uptake assay for the estimation of cell viability/cytotoxicity
-
Repetto G, del Peso A, Zurita JL. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat Protoc 2008;3:1125-31.
-
(2008)
Nat Protoc
, vol.3
, pp. 1125-1131
-
-
Repetto, G.1
Del Peso, A.2
Zurita, J.L.3
-
29
-
-
79957999601
-
Chromatin dynamics of gene activation and repression in response to interferon alpha (IFN(alpha)) reveal new roles for phosphorylated and unphosphorylated forms of the transcription factor STAT2
-
Testoni B, Völlenkle C, Guerrieri F, et al. Chromatin dynamics of gene activation and repression in response to interferon alpha (IFN(alpha)) reveal new roles for phosphorylated and unphosphorylated forms of the transcription factor STAT2. J Biol Chem 2011;286:20217-27.
-
(2011)
J Biol Chem
, vol.286
, pp. 20217-20227
-
-
Testoni, B.1
Völlenkle, C.2
Guerrieri, F.3
-
30
-
-
44949138461
-
A rapid micro chromatin immunoprecipitation assay (microChIP)
-
Dahl JA, Collas P. A rapid micro chromatin immunoprecipitation assay (microChIP). Nat Protoc 2008;3:1032-45.
-
(2008)
Nat Protoc
, vol.3
, pp. 1032-1045
-
-
Dahl, J.A.1
Collas, P.2
-
31
-
-
77953893773
-
Ribavirin improves early responses to peginterferon through improved interferon signaling
-
Feld JJ, Lutchman GA, Heller T, et al. Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology 2010;139:154-62.e4.
-
(2010)
Gastroenterology
, vol.139
, pp. 154-154e4
-
-
Feld, J.J.1
Lutchman, G.A.2
Heller, T.3
-
32
-
-
0038032916
-
Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells
-
Zhang Y, Jamaluddin M, Wang S, et al. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J Virol 2003;77:5933-47.
-
(2003)
J Virol
, vol.77
, pp. 5933-5947
-
-
Zhang, Y.1
Jamaluddin, M.2
Wang, S.3
-
33
-
-
78049375674
-
General review on in vitro hepatocyte models and their applications
-
Guguen-Guillouzo C, Guillouzo A. General review on in vitro hepatocyte models and their applications. Methods Mol Biol Clifton NJ 2010;640:1-40.
-
(2010)
Methods Mol Biol Clifton NJ
, vol.640
, pp. 1-40
-
-
Guguen-Guillouzo, C.1
Guillouzo, A.2
-
34
-
-
84884981804
-
Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin
-
Mori K, Hiraoka O, Ikeda M, et al. Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin. Hepatol Baltim Md 2013;58:1236-44.
-
(2013)
Hepatol Baltim Md
, vol.58
, pp. 1236-1244
-
-
Mori, K.1
Hiraoka, O.2
Ikeda, M.3
-
35
-
-
34249299791
-
The complex language of chromatin regulation during transcription
-
Berger SL. The complex language of chromatin regulation during transcription. Nature 2007;447:407-12.
-
(2007)
Nature
, vol.447
, pp. 407-412
-
-
Berger, S.L.1
-
36
-
-
79960913181
-
Genome-wide integration on transcription factors, histone acetylation and gene expression reveals genes co-regulated by histone modification patterns
-
Natsume-Kitatani Y, Shiga M, Mamitsuka H. Genome-wide integration on transcription factors, histone acetylation and gene expression reveals genes co-regulated by histone modification patterns. PloS ONE 2011;6:e22281.
-
(2011)
PloS ONE
, vol.6
-
-
Natsume-Kitatani, Y.1
Shiga, M.2
Mamitsuka, H.3
-
37
-
-
33846783261
-
Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase
-
Kubicek S, O'Sullivan RJ, August EM, et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell 2007;25:473-81.
-
(2007)
Mol Cell
, vol.25
, pp. 473-481
-
-
Kubicek, S.1
O'Sullivan, R.J.2
August, E.M.3
-
38
-
-
84861722003
-
Histone H3 lysine 9 di-methylation as an epigenetic signature of the interferon response
-
Fang TC, Schaefer U, Mecklenbrauker I, et al. Histone H3 lysine 9 di-methylation as an epigenetic signature of the interferon response. J Exp Med 2012;209:661-9.
-
(2012)
J Exp Med
, vol.209
, pp. 661-669
-
-
Fang, T.C.1
Schaefer, U.2
Mecklenbrauker, I.3
-
39
-
-
84881087434
-
Permissivity of primary human hepatocytes and different hepatoma cell lines to cell culture adapted hepatitis C virus
-
Helle F, Brochot E, Fournier C, et al. Permissivity of primary human hepatocytes and different hepatoma cell lines to cell culture adapted hepatitis C virus. PloS ONE 2013;8:e70809.
-
(2013)
PloS ONE
, vol.8
-
-
Helle, F.1
Brochot, E.2
Fournier, C.3
-
40
-
-
84870567022
-
IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection
-
Park H, Serti E, Eke O, et al. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatol Baltim Md 2012;56:2060-70.
-
(2012)
Hepatol Baltim Md
, vol.56
, pp. 2060-2070
-
-
Park, H.1
Serti, E.2
Eke, O.3
-
41
-
-
78049401342
-
The HepaRG cell line: Biological properties and relevance as a tool for cell biology, drug metabolism, and virology studies
-
Marion M-J, Hantz O, Durantel D. The HepaRG cell line: biological properties and relevance as a tool for cell biology, drug metabolism, and virology studies. Methods Mol Biol Clifton NJ 2010;640:261-72.
-
(2010)
Methods Mol Biol Clifton NJ
, vol.640
, pp. 261-272
-
-
Marion, M.-J.1
Hantz, O.2
Durantel, D.3
-
42
-
-
79952305174
-
Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C
-
Dill MT, Duong FHT, Vogt JE, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011;140:1021-31.
-
(2011)
Gastroenterology
, vol.140
, pp. 1021-1031
-
-
Dill, M.T.1
Duong, F.H.T.2
Vogt, J.E.3
-
43
-
-
84896480771
-
Ribavirin for chronic hepatitis e virus infection in transplant recipients
-
Kamar N, Izopet J, Tripon S, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med 2014;370:1111-20.
-
(2014)
N Engl J Med
, vol.370
, pp. 1111-1120
-
-
Kamar, N.1
Izopet, J.2
Tripon, S.3
-
44
-
-
84892740572
-
Respiratory syncytial virus disease: Prevention and treatment
-
Chu HY, Englund JA. Respiratory syncytial virus disease: prevention and treatment. Curr Top Microbiol Immunol 2013;372:235-58.
-
(2013)
Curr Top Microbiol Immunol
, vol.372
, pp. 235-258
-
-
Chu, H.Y.1
Englund, J.A.2
-
45
-
-
84880056374
-
Intervention strategies for emerging viruses: Use of antivirals
-
Debing Y, Jochmans D, Neyts J. Intervention strategies for emerging viruses: use of antivirals. Curr Opin Virol 2013;3:217-24.
-
(2013)
Curr Opin Virol
, vol.3
, pp. 217-224
-
-
Debing, Y.1
Jochmans, D.2
Neyts, J.3
-
46
-
-
0015523596
-
Broad-spectrum Antiviral Activity of Virazole: 1-beta-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide
-
Sidwell RW, Huffman JH, Khare GP, et al. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide. Science 1972;177:705-6.
-
(1972)
Science
, vol.177
, pp. 705-706
-
-
Sidwell, R.W.1
Huffman, J.H.2
Khare, G.P.3
-
47
-
-
84865791569
-
Ribavirin therapy for hepatitis e virus-induced acute on chronic liver failure: A preliminary report
-
Goyal R, Kumar A, Panda SK, et al. Ribavirin therapy for hepatitis E virus-induced acute on chronic liver failure: a preliminary report. Antivir Ther 2012;17:1091-6.
-
(2012)
Antivir Ther
, vol.17
, pp. 1091-1096
-
-
Goyal, R.1
Kumar, A.2
Panda, S.K.3
-
48
-
-
84876093975
-
Ribavirin treatment of acute and chronic hepatitis E: A single-centre experience
-
Pischke S, Hardtke S, Bode U, et al. Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. Liver Int Off J Int Assoc Study Liver 2013;33:722-6.
-
(2013)
Liver Int off J Int Assoc Study Liver
, vol.33
, pp. 722-726
-
-
Pischke, S.1
Hardtke, S.2
Bode, U.3
-
49
-
-
0032896077
-
Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C
-
McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999;19(Suppl 1):57-65.
-
(1999)
Semin Liver Dis
, vol.19
, pp. 57-65
-
-
McHutchison, J.G.1
Poynard, T.2
-
50
-
-
0037179698
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
-
Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
-
(2002)
N Engl J Med
, vol.347
, pp. 975-982
-
-
Fried, M.W.1
Shiffman, M.L.2
Reddy, K.R.3
-
51
-
-
84907525692
-
Sofosbuvir/ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients decompensated genotype-1 patients and genotype-1 patients with prior sofosbuvir treatment experience
-
Gane EJ, Hyland RH, An D, et al. Sofosbuvir/ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients, and genotype-1 patients with prior sofosbuvir treatment experience. J Hepatol 2014;60:S3-4.
-
(2014)
J Hepatol
, vol.60
, pp. S3-4
-
-
Gane, E.J.1
Hyland, R.H.2
An, D.3
-
52
-
-
84905492815
-
Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome
-
Meissner EG, Wu D, Osinusi A, et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 2014;124:3352-63.
-
(2014)
J Clin Invest
, vol.124
, pp. 3352-3363
-
-
Meissner, E.G.1
Wu, D.2
Osinusi, A.3
-
53
-
-
0035811016
-
RNA virus error catastrophe: Direct molecular test by using ribavirin
-
Crotty S, Cameron CE, Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci USA 2001;98:6895-900.
-
(2001)
Proc Natl Acad Sci USA
, vol.98
, pp. 6895-6900
-
-
Crotty, S.1
Cameron, C.E.2
Andino, R.3
-
54
-
-
0032428770
-
Respiratory syncytial virus (RSV) disease and prospects for its control
-
Wyde PR. Respiratory syncytial virus (RSV) disease and prospects for its control. Antiviral Res 1998;39:63-79.
-
(1998)
Antiviral Res
, vol.39
, pp. 63-79
-
-
Wyde, P.R.1
-
55
-
-
84874107832
-
Perspectives and challenges of interferon-free therapy for chronic hepatitis C
-
Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013;58:583-92.
-
(2013)
J Hepatol
, vol.58
, pp. 583-592
-
-
Lange, C.M.1
Zeuzem, S.2
|